Skip to main content
. Author manuscript; available in PMC: 2021 May 1.
Published in final edited form as: Mov Disord. 2020 Feb 19;35(5):833–844. doi: 10.1002/mds.27989

TABLE 1.

Demographics and PD characteristics

Variable GBA PD LRRK2 PD sPD
BL Visit, N = 80 BL Visit, N = 158 Year 2 Visit, N = 361
Age, mean (SD) 62.7 (9.9) 63.8 (9.2) 63.8 (9.7)
Sex, male, n (%) 43 (53.8)a 76 (48.1)a 238 (65.9)
Education, <13 y, n (%) 12 (15.0) 35 (22.2) 62 (17.2)
Ethnicity, Hispanic/Latino, n (%) 1 (1.3) 39 (24.7)a,b 8 (2.2)
Race, n (%)
 White 76 (95.0) 139 (88.5) 332 (92.0)
 Missing 0 1 0
Family history of PD, n (%)
 First degree 18 (22.8) 72 (47.1)a, b 47 (13.1)
 Second degree 11 (13.9) 25 (16.3) 42 (11.7)
 None 50 (63.3) 56 (36.6) 271 (75.3)
 Missing 1 5 1
Genetic mutation, n (%)
 G2019S 0 (0.0) 140 (88.6)
 R1441C 0 (0.0) 1 (0.6)
 R1441G 0 (0.0) 16 (10.1)
 N1437H 0 (0.0) 1 (0.6)
 N370S (c. 1226A>G) 71 (88.8) 0 (0.0)
 L483P or L444P (c.1448T > C) 6 (7.5) 0 (0.0)
 84GG (c.84_85insG) 3 (3.8) 0 (0.0)
Disease duration, y
 Mean (SD) 3.1 (2.0) 2.9 (1.9) 2.6 (0.6)
 Median (minimum, maximum) 3.0 (0.0, 7.1)c 2.4 (0.1, 6.9) 2.4 (2.0, 4.9)d
Age at PD symptom onset, mean (SD) 58.4 (10.7) 58.8 (9.9) 59.7 (9.9)
a

P < 0.05 versus sPD.

b

P < 0.05 versus GBA PD.

c

Two GBA PD subjects had disease durations <7 years at screening, but exceeded 7 years by the time of their baseline assessment.

d

Seven sPD subjects had disease durations <2 years at screening, but exceeded 4 years at year 2 as a result of scheduling delays; 10 sPD subjects had disease durations >2 years at screening, but a waiver was granted allowing them to enroll in the study.

Report generated on data submitted as of July 1, 2019. P values were found using t tests (age and age at PD symptom onset), Wilcoxon rank-sum tests (disease duration), and χ2 tests (all categorical variables).

PD, Parkinson’s disease; GBA, glucosylceramidase beta; LRRK2, leucine rich kinase 2; sPD, sporadic PD; BL, baseline; SD, standard deviation.